Cargando…
Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?
Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling-up implementation. The WHO and UNAIDS have made PrEP implementation a priority for populations at highest risk,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879931/ https://www.ncbi.nlm.nih.gov/pubmed/29609619 http://dx.doi.org/10.1186/s12977-018-0408-3 |
_version_ | 1783311084346671104 |
---|---|
author | Eakle, Robyn Venter, Francois Rees, Helen |
author_facet | Eakle, Robyn Venter, Francois Rees, Helen |
author_sort | Eakle, Robyn |
collection | PubMed |
description | Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling-up implementation. The WHO and UNAIDS have made PrEP implementation a priority for populations at highest risk, and several countries have developed guidelines and national plans accordingly, largely based on evidence generated by demonstration projects. PrEP presents the opportunity to change the face of HIV prevention by offering a new option for protection against HIV and disrupting current HIV prevention systems. Nevertheless, as with all new technologies, both practical and social requirements for implementation must be taken into account if there is to be sustained and widespread adoption, which will also apply to forthcoming prevention technologies. Defining and building success for PrEP within the scope of scale-up requires careful consideration. This review summarises where the PrEP field is today, lessons learned from the past, the philosophy and practicalities of how successful programming may be defined, and provides perspectives of costs and affordability. We argue that a successful PrEP programme is about effective intervention integration and ultimately keeping people HIV negative. |
format | Online Article Text |
id | pubmed-5879931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58799312018-04-04 Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? Eakle, Robyn Venter, Francois Rees, Helen Retrovirology Review Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling-up implementation. The WHO and UNAIDS have made PrEP implementation a priority for populations at highest risk, and several countries have developed guidelines and national plans accordingly, largely based on evidence generated by demonstration projects. PrEP presents the opportunity to change the face of HIV prevention by offering a new option for protection against HIV and disrupting current HIV prevention systems. Nevertheless, as with all new technologies, both practical and social requirements for implementation must be taken into account if there is to be sustained and widespread adoption, which will also apply to forthcoming prevention technologies. Defining and building success for PrEP within the scope of scale-up requires careful consideration. This review summarises where the PrEP field is today, lessons learned from the past, the philosophy and practicalities of how successful programming may be defined, and provides perspectives of costs and affordability. We argue that a successful PrEP programme is about effective intervention integration and ultimately keeping people HIV negative. BioMed Central 2018-04-02 /pmc/articles/PMC5879931/ /pubmed/29609619 http://dx.doi.org/10.1186/s12977-018-0408-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Eakle, Robyn Venter, Francois Rees, Helen Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title_full | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title_fullStr | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title_full_unstemmed | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title_short | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
title_sort | pre-exposure prophylaxis (prep) in an era of stalled hiv prevention: can it change the game? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879931/ https://www.ncbi.nlm.nih.gov/pubmed/29609619 http://dx.doi.org/10.1186/s12977-018-0408-3 |
work_keys_str_mv | AT eaklerobyn preexposureprophylaxisprepinaneraofstalledhivpreventioncanitchangethegame AT venterfrancois preexposureprophylaxisprepinaneraofstalledhivpreventioncanitchangethegame AT reeshelen preexposureprophylaxisprepinaneraofstalledhivpreventioncanitchangethegame |